HRT and extragenital diseases: 2013 evidence
https://doi.org/10.21518/2079-701X-2013-8-20-21
Abstract
With the environmental situation getting worse every year, unhealthy diet, adynamia and sleep-wake cycle imbalance, the health of Russian people is deteriorating. The incidence of diseases of civilization has been steadily increasing: today, they are the major reasons of female mortality.
About the Authors
V. E. Radzinskiy
People's Friendship University of Russia
Russian Federation
Russian Federation
R. Yu. Yeremichev
People's Friendship University of Russia
Russian Federation
Russian Federation
References
1. Гинекология. Национальное руководство / под ред. Г.М. Савельевой, В.И. Кулакова, И.Б. Манухина. М.: ГЭОТАР-Медиа, 2011.
2. Гинекология. Руководство к практическим занятиям / под ред. В.Е. Радзинского. М.: ГЭОТАР-Медиа, 2013.
3. Sturdee D.W., Pines A. and all. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health // Climacteric. №14. Р. 302–320. June 2011.
4. Nick Panay, Haitham Hamoda, Roopen Arya, Michael Savvas and all. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy // Menopause Int. published online 23 May 2013.
5. Joseph A. Caprini, MD. Thrombosis Risk Assessment as a Guide to Quality Patient Care. February/March 2005.
6. Marianne Canonico, Geneviève Plu-Bureau, Gordon D.O. Lowe, Pierre-Yves Scarabin. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis // BMJ. 2008. May 31. №336(7655). Р. 1227–1231. Published online 2008 May 20. doi: 10.1136/bmj.39555.441944.BE.
7. Ichikawa A., Sumino H., Ogawa T., Ichikawa S., Nitta K. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin-aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women // Geriatr. Gerontol. Int. 2008. Dec. №8(4). Р. 259–264. doi: 10.1111/j.1447-0594.2008.00474.x.
8. Preston R.A. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women // Climacteric. 2009. №12 (Suppl. 1). Р. 66–70.
9. Chiu C.L., Lujic S., Thornton C., O'Loughlin A., Makris A., Hennessy A., Lind J.M. Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study // PLoS One. 2012. №7(7). e40260. doi: 10.1371/journal.pone.0040260. Epub 2012 Jul 11.
10. Ditte-Marie Bretler, Peter Riis Hansen, Jesper Lindhardsen, Ole Ahlehoff, Charlotte Andersson, Thomas Bo Jensen, Jakob Raunsø, Christian Torp-Pedersen, and Gunnar Hilmar Gislason. Hormone Replacement Therapy and Risk of New-Onset Atrial Fibrillation after Myocardial Infarction - A Nationwide Cohort Study / PLoS One. 2012. №7(12). e51580. Published online 2012 December 17. doi: 10.1371/journal.pone.0051580
11. Moyer, Virginia A. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S.Preventive Services Task Force recommendation statement. 2013 Jan 1.
12. Moore B., Paterson M., Sturdee D. Effect of oral hormone replacement therapy on liver function tests // Maturitas. 1987. Apr. №9(1). Р. 7–15.
13. Codes L., Asselah T. and all. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy // Gut. 2007. Mar. №56(3). Р. 390–395.
14. Rudic J.S., Poropat G. and all. Hormone replacement for osteoporosis in women with primary biliary cirrhosis // Cochrane Database Syst. Rev. 2011. Dec. №7(12). CD009146. doi: 10.1002/14651858.CD009146.pub2.
15. Kanis J.A., McCloskey E.V. and all. European guidance for the diagnosis and management of osteoporosis in postmenopausal women // Osteoporos Int. 2013. Jan. №24(1). Р. 23–57. doi: 10.1007/s00198-012-2074-y. Epub 2012 Oct. 19.
16. Dane C., Dane B., Cetin A., Erginbas M. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis // Gynecol. Endocrinol. 2007. Jul. №23(7). Р. 398–403.
17. Genazzani A.R., Schmelter T., Schaefers M., Gerlinger C., Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women // Climacteric. 2013. Aug. №16(4). Р. 490–498. doi: 10.3109/13697137.2013.783797. Epub 2013 May 11.
18. L'hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT // Climacteric. 2013. Aug. №16 (Suppl. 1). Р. 44–53. doi: 10.3109/13697137.2013.808563.
Review
For citations:
Radzinskiy VE, Yeremichev RY. HRT and extragenital diseases: 2013 evidence. Meditsinskiy sovet = Medical Council. 2013;(8):20-21. (In Russ.) https://doi.org/10.21518/2079-701X-2013-8-20-21
Views:
362
Email this article 